Small dense LDL: An emerging risk factor for cardiovascular disease

Area of Science:

• Cardiovascular Medicine
• Biochemistry
• Clinical Chemistry

Background:

• Low-density lipoprotein cholesterol (LDL-C) is a key coronary artery disease (CAD) risk factor, but levels aren't always high in CAD patients.
• LDL particles vary in size, density, and composition; small dense LDL (sd-LDL) predominance is strongly associated with CAD.
• Elevated sd-LDL cholesterol (sd-LDL-C) is observed in high-risk groups like type 2 diabetes and metabolic syndrome patients, establishing sd-LDL as a potential CAD surrogate marker.

Purpose of the Study:

• To evaluate the clinical utility of small dense LDL cholesterol (sd-LDL-C) as a marker for coronary artery disease (CAD).
• To assess the potential of a new homogeneous assay for sd-LDL-C measurement in large-scale clinical studies.
• To determine if sd-LDL-C is a superior marker to LDL-C and if therapies targeting sd-LDL-C reduce CAD incidence.

Main Methods:

• Review of existing literature on LDL subclasses and their association with CAD.
• Introduction of a novel, pretreatment-free, detergent-based homogeneous assay for sd-LDL-C.
• Highlighting the assay's reproducibility and suitability for automated analyzers and large-scale clinical applications.

Main Results:

• Accumulating evidence links a predominance of small dense LDL (sd-LDL) to CAD.
• sd-LDL-C concentrations are elevated in high-risk populations, supporting its role as a surrogate marker.
• A new homogeneous assay offers reproducible, automated measurement of sd-LDL-C, suitable for clinical studies.

Conclusions:

• Standardization of sd-LDL separation methods and particle definitions is needed.
• The newly developed homogeneous assay for sd-LDL-C is a promising tool for clinical research.
• Further studies using this assay are crucial to confirm sd-LDL-C's superiority over LDL-C and evaluate the efficacy of sd-LDL-C-targeted therapies in reducing CAD incidence.